DexCom (DXCM) Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DXCM shares.
View DXCM analyst ratings or view top-rated stocks.

13 Wall Street analysts have issued 1 year price targets for DexCom's stock. Their DXCM share price forecasts range from $105.00 to $150.00. On average, they anticipate the company's share price to reach $126.81 in the next twelve months. This suggests a possible upside of 8.3% from the stock's current price.
View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts.

DexCom's stock was trading at $113.24 at the start of the year. Since then, DXCM shares have increased by 3.4% and is now trading at $117.13.
View the best growth stocks for 2023 here.

DexCom saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 12,730,000 shares, an increase of 5.4% from the April 15th total of 12,080,000 shares. Based on an average daily trading volume, of 2,350,000 shares, the days-to-cover ratio is currently 5.4 days.
View DexCom's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our DXCM earnings forecast.

DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings data on Thursday, April, 27th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.02. The medical device company earned $7.45 billion during the quarter, compared to the consensus estimate of $720.52 million. DexCom had a trailing twelve-month return on equity of 18.29% and a net margin of 9.68%. DexCom's revenue for the quarter was up 1085.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.08 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Global X Internet of Things ETF (SNSR), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA), Global X Telemedicine & Digital Health ETF (EDOC), American Century Mid Cap Growth Impact (MID), Simplify Health Care ETF (PINK), Fidelity Digital Health ETF (FDHT) and Neuberger Berman Disrupters ETF (NBDS).

DexCom's stock split on the morning of Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were issued to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

DexCom updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.40 billion-$3.52 billion, compared to the consensus revenue estimate of $3.47 billion.

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (4.43%), Sands Capital Management LLC (3.54%), Geode Capital Management LLC (2.14%), Jennison Associates LLC (1.87%), Bank of New York Mellon Corp (1.29%) and Blair William & Co. IL (1.12%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends.

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DXCM stock can currently be purchased for approximately $117.13.

DexCom (NASDAQ:DXCM) has a market capitalization of $45.40 billion and generates $2.91 billion in revenue each year. The medical device company earns $341.20 million in net income (profit) each year or $0.70 on an earnings per share basis.

The company employs 7,600 workers across the globe.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201.